Abstract Number: 0820 • ACR Convergence 2024
The Classification in Axial Spondyloarthritis Inception Cohort Study: Performance of the 2009 Assessments in Spondyloarthritis International Society Classification Criteria
Background/Purpose: The 2009 ASAS classification criteria had sensitivity of 83% and specificity of 84% for a rheumatologist diagnosis of axSpA. However, their implementation revealed varying…Abstract Number: 2057 • ACR Convergence 2024
Clinical Features of Autoimmune Uveitis and Associated Factors with Reactivation Subtype Presentation from a Peruvian Multidisciplinary Reference Center
Background/Purpose: To determine clinical features of autoimmune uveitis (AU) and the associated factors with the reactivation subtype Methods: A transversal analysis from single center cohort (ophthalmologic/rheumatologic…Abstract Number: 0352 • ACR Convergence 2024
Fast-tracking Axial Spondyloarthritis Diagnosis: A Novel Approach to Public Health Advocacy and Awareness
Background/Purpose: The Act on Axial SpA campaign is dedicated to minimising the lengthy 8.5-year delay in diagnosing axial spondyloarthritis (axial SpA) by implementing a pioneering…Abstract Number: 0821 • ACR Convergence 2024
Validation of ASAS Preliminary Data-Driven MRI Lesion Cut-offs for a Positive MRI of the Sacroiliac Joints in Patients with Axial Spondyloarthritis and Subgroups with Psoriasis, Iritis, and Colitis
Background/Purpose: Recent analysis of MRI scans from the 2009 ASAS classification cohort has led to a new proposal for the application of more stringent MRI…Abstract Number: 2153 • ACR Convergence 2024
Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Background/Purpose: Patients with psoriasis often present with musculoskeletal (MSK) symptoms, yet validated instruments to measure MSK symptoms in this population are limited. The IDEOM MSK-Q…Abstract Number: 0356 • ACR Convergence 2024
Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study
Background/Purpose: Biosimilars (BioS) are cost-effective alternatives to reference products for patients with chronic inflammatory rheumatic diseases (CIRD) and inflammatory bowel diseases (IBD), but treatment adherence…Abstract Number: 0851 • ACR Convergence 2024
Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site
Background/Purpose: Enthesitis is a key domain in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aims to develop a new PsA-specific sonographic scoring…Abstract Number: 2334 • ACR Convergence 2024
Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS)
Background/Purpose: Axial involvement, affecting the sacroiliac joints (SIJ) and/or spine, is a clinically relevant manifestation of psoriatic arthritis (PsA) that can influence management strategies. Previous…Abstract Number: 0359 • ACR Convergence 2024
SpA Disk©: A New Tool to Monitor the QoL of Spondyloarthritis Patients
Background/Purpose: Spondyloarthritis (SpA) significantly affects patients' quality of life (QoL). Current tools in routine medical practice primarily focus on assessing disease activity, neglecting the broader…Abstract Number: 1025 • ACR Convergence 2024
Gender Disparities in Disease Impact and Treatment Access for Spondyloarthropathies in Latin America: Insights from a Web Survey
Background/Purpose: Previous studies have shown that female patients with spondyloarthritis (SpA) tend to experience a greater impact on their functionality, especially among women in Latin…Abstract Number: 2354 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
Background/Purpose: To assess baseline demographics and clinical characteristics of patients with PsA that are most associated with achievement of clinical response to intravenous (IV) secukinumab…Abstract Number: 0541 • ACR Convergence 2024
Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial
Background/Purpose: Understanding the best-performing disease activity measure and response criterion in peripheral spondyloarthritis (pSpA) is crucial for the development of future meaningful clinical studies. The…Abstract Number: 1433 • ACR Convergence 2024
Association of Contextual Factors with Sonographic Inflammatory and Structural Phenotypes in Psoriatic Arthritis Patients
Background/Purpose: Ultrasound (US) is a valuable tool for enhancing disease activity assessment in psoriatic arthritis (PsA) by providing detailed visualization of both inflammatory and structural…Abstract Number: 2358 • ACR Convergence 2024
Integration of Single-cell Multi-omics Profiling for Investigating Treatment Response to Tumor Necrosis Factor Alpha Inhibitors in Patients with Axial Spondyloarthritis
Background/Purpose: In cases where patients continue to experience active symptoms despite receiving maximum doses of nonsteroidal anti-inflammatory drug therapy in patients with axial spondyloarthritis (axSpA),…Abstract Number: 0546 • ACR Convergence 2024
Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting 1.4% of the US adult population. The leading clinical symptom of axSpA is chronic inflammatory…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »